๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Neoadjuvant Therapy
Clinical trial register · China

Neoadjuvant Therapy Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 6
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai6
All 1 locations
Target enrolment
to

Neoadjuvant Therapy trials in China

6 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Digital Mind-Body Therapy for Neoadjuvant Breast Cancer
NCT07541664Neoadjuvant Therapy
Fudan University
Not applicable
66
Shanghai
2026-03-25
Not yet open
Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
NCT07156604NSCLC, Neoadjuvant Therapy
Fudan University
Phase 2
30
Shanghai
2025-09-30
Recruiting
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
NCT07150949Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Fudan University
Phase 2
138
Shanghai
2025-08-28
Recruiting
Neoadjuvant SNF Precision Therapy Phase III
NCT06913777Neoadjuvant Therapy
Fudan University
Phase 3
404
Shanghai
2025-04-08
Not yet open
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
NCT06404736Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
Fudan University
Phase 2
73
Shanghai
2024-05-07
Recruiting
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
NCT06281405Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Fudan University
Phase 2
192
Shanghai
2024-03-28
Rows per page Showing 1–6 of 6
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/condition/neoadjuvant-therapy

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 6 of those studies listing the condition Neoadjuvant Therapy that also match the filters currently applied.

How many Neoadjuvant Therapy trials are recruiting in China?

4 of the 6 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Neoadjuvant Therapy), 6 studies
PhaseStudiesRecruitingShare
Phase 24266.7%
Not applicable1116.7%
Phase 31116.7%

Most active sponsors

Lead sponsors with the most studies (Neoadjuvant Therapy)
Lead sponsorStudiesRecruiting
Fudan University64
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.